Skip to main content
REYON PHARMACEUTICAL CO., LTD logo

REYON PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 102460 ISIN · KR7102460003 KO Manufacturing
Open in API
Filings indexed 227 across all filing types
Latest filing 2026-06-01 Governance Information
Country KR South Korea
Listing KO 102460

About REYON PHARMACEUTICAL CO., LTD

https://www.reyonpharm.co.kr/

REYON PHARMACEUTICAL CO., LTD. is a research-driven company engaged in the development and manufacturing of chemical and biopharmaceutical products. Its primary business areas encompass the production of Active Pharmaceutical Ingredients (APIs), a diverse portfolio of generic medicines, and contrast agents. The company leverages advanced synthesis know-how to supply high-value APIs to domestic and international partners. A key strategic focus is the development of next-generation biopharmaceuticals, including gene therapies for conditions like wet age-related macular degeneration and NK cell therapies for solid cancers. Reyon is also expanding its capabilities to offer contract development and manufacturing (CDMO) services for complex biologic drugs.

Recent filings

Filing Released Lang Actions
기업지배구조보고서공시
Governance Information Classification · 92% confidence The document is a full Corporate Governance Report (“기업지배구조 보고서 신고서”) containing detailed disclosures on board composition, governance policies, shareholder meeting procedures, governance key metrics, and internal governance rules. It is not merely an announcement or proxy materials but the substantive governance report itself, matching the definition of Governance Information (CGR).
2026-06-01 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 93% confidence The document is titled ‘분기보고서’ for the 63rd fiscal term covering 2026-01-01 to 2026-03-31. It is a comprehensive quarterly report filed with the Financial Services Commission and Korea Exchange, including detailed financial statements, business overview, subsidiaries, capital changes, stock information, product lines, raw materials, and operating results for the quarter. This clearly matches an Interim/Quarterly Report, not merely an earnings release or announcement. Therefore, it should be classified as IR (Interim/Quarterly Report). Q1 2026
2026-05-15 Korean
사외이사의선임ㆍ해임또는중도퇴임에관한신고
Board/Management Information Classification · 98% confidence The document is a formal notification filed with the Financial Services Commission/Korea Exchange regarding the appointment, reappointment, dismissal, or mid-term resignation of outside directors (sa-oe-i-sa). It lists details of the board composition before and after changes and biographical information for new outside directors. This matches the definition of a Board/Management Information filing (code MANG).
2026-03-30 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 94% confidence The document is titled “정기주주총회 결과” (Regular Shareholders’ Meeting Results) and contains detailed vote outcomes for each agenda item (approval of financial statements, director appointments, remuneration limits, etc.), along with voting percentages and meeting details. This matches the definition for Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-03-30 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from E-Wha Pharm. It provides the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and auditor information. While it contains financial data, it is a summary disclosure of the audit results rather than the full Annual Report (10-K) or a standalone audit report document. In the context of Korean regulatory filings (DART/KIND), this specific format is a standard disclosure of audit results, which falls under the 'Audit Report / Information' category. FY 2025
2026-03-20 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 99% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Lee-Yeon Pharmaceutical Co., Ltd. It includes the independent auditor's report, financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, Statement of Cash Flows), and detailed notes to the financial statements for the fiscal years 2024 and 2025. It is not an Annual Report (10-K) as it focuses specifically on the audit and financial statements rather than the full business activity report, and it is not an announcement (RPA) because it contains the full financial data. FY 2025
2026-03-20 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.